A Phase 4 interventional study of Contrast agent in Contrast Agent, Endothelial Function and Cytokines, sponsored by Xiang Guang-da. Completed at 1 site in China. Open to male participants aged 20 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-13.
Sponsored by Xiang Guang-da · Phase 4, Interventional, and Health services research
Contrast medium is essential for diagnosis of many diseases. However, recent studies showed that contrast agents can induce renal injury and is associated with poor long-term clinical outcome, especially in diabetes. To date, no data are available on the relationship between contrast medium and endothelial function. Endothelial dysfunction is known to precede atherosclerosis and is considered a risk marker for future development of cardiovascular disease. Therefore, we hypothesized that contrast agents may induce endothelial dysfunction in healthy men. In addition, we hypothesized that contrast induced endothelial dysfunction via free radicals. Thus, we also test alpha-lipoic acid whether or not protect endothelial dysfunction induced by contrast agents.
Xiang Guang-da is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
Other: Contrast agent
Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
Other: Contrast agent
The endothelial dysfunction and the protective role of alpha-lipoic acid
Time frame: 6 months
The apoptosis of endothelial progenitor cell
Time frame: 6 months
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiang Guang-da